Becton, Dickinson and Co. (BD) said Monday that it has acquired CRISI Medical Systems, a technology company that improves IV injectable medications.
The acquisition assists BD, a leading technology company that innovates for the medical industry around the world, with its goal of remedying preventable errors in medications and deliveries.
The two companies previously agreed to a partnership in 2013. Through this partnership, the two created the BD Intelliport Medication Management System. The system is the first of its kind that can manage manual IV bolus injections. It identifies the drug, the allergies and the dose measurement and sends the information to each patient’s electronic medical record. Since the system received U.S. Food and Drug Administration approval in December 2014, health professionals will begin implementing the system in 2015.
"We are very excited about the CRISI acquisition,” BD Medical Segment President Tom Polen said. “It gives BD access to the injection safety market with a differentiated platform that we believe, when combined with our pending CareFusion acquisition, will significantly enhance our growing end-to-end IV medication safety offering. The Intelliport system fills a need that has remained unmet for decades – the use of technology to reduce the likelihood of human error in the practice of injectable medication delivery."
Financial details about the acquisition were not available.
"We found the perfect partner in BD and are very pleased to have been on this journey together to create and introduce the Intelliport system to the medical community," CRISI CEO Michael Perry said.